SNA 11
Alternative Names: SNA-11; Synxyrin®Latest Information Update: 28 May 2024
At a glance
- Originator SyneuRx International (Taiwan) corp
- Class Antidepressants
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Major depressive disorder(Treatment-resistant) in Taiwan
- 23 Sep 2022 SyneuRX plans a phase-II trial in Major depressive disorder in USA (SyneuRX pipeline, September 2022).
- 31 Mar 2021 Phase-I clinical trials in Major depressive disorder (Treatment resistant) in Taiwan (unspecified route) (SyneuRX pipeline; September 2022)